Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Documenti analoghi

• Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
  di: ZHANG Shan, et al.
  Pubblicazione: (2023-04-01)
• Tuberculous hemorrhagic meningoencephalitis. A rare manifestation of miliary TB. Case report and review
  di: Layth Raafat Hamzeh, et al.
  Pubblicazione: (2025-05-01)
• Consideration on " Patient-Centered" Drug Development for Rare Diseases
  di: TANG Ling, et al.
  Pubblicazione: (2024-04-01)
• Appraisal Concerns for the Clinical Research and Development of Drugs for Rare Diseases
  di: TANG Ling, et al.
  Pubblicazione: (2022-01-01)
• Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases
  di: LI Kexin, et al.
  Pubblicazione: (2023-10-01)